JNJ

233.69

+2.09%↑

ISRG

480.13

-3.45%↓

ABT

108.82

-0.38%↓

RDY

13.8

+2.45%↑

NEOG

10.27

-1.53%↓

JNJ

233.69

+2.09%↑

ISRG

480.13

-3.45%↓

ABT

108.82

-0.38%↓

RDY

13.8

+2.45%↑

NEOG

10.27

-1.53%↓

JNJ

233.69

+2.09%↑

ISRG

480.13

-3.45%↓

ABT

108.82

-0.38%↓

RDY

13.8

+2.45%↑

NEOG

10.27

-1.53%↓

JNJ

233.69

+2.09%↑

ISRG

480.13

-3.45%↓

ABT

108.82

-0.38%↓

RDY

13.8

+2.45%↑

NEOG

10.27

-1.53%↓

JNJ

233.69

+2.09%↑

ISRG

480.13

-3.45%↓

ABT

108.82

-0.38%↓

RDY

13.8

+2.45%↑

NEOG

10.27

-1.53%↓

Search

Embecta Corp

Avatud

SektorTervishoid

10.86 -2.16

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

10.82

Max

11.31

Põhinäitajad

By Trading Economics

Sissetulek

-19M

26M

Müük

-32M

264M

P/E

Sektori keskmine

6.63

90.422

Dividenditootlus

5.48

Kasumimarginaal

10

Töötajad

1,850

EBITDA

-40M

71M

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

5.48%

2.13%

Järgmine tulemuste avaldamine

5. veebr 2026

Järgmine dividendimakse kuupäev

13. märts 2026

Järgmine aktsia dividendi kuupäev (ex-date)

27. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

-158M

636M

Eelmine avamishind

13.02

Eelmine sulgemishind

10.86

Uudiste sentiment

By Acuity

38%

62%

107 / 352 Pingereas Healthcare

Embecta Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. veebr 2026, 23:52 UTC

Omandamised, ülevõtmised, äriostud

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2. veebr 2026, 23:52 UTC

Omandamised, ülevõtmised, äriostud

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2. veebr 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2. veebr 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2. veebr 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2. veebr 2026, 23:23 UTC

Tulu

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2. veebr 2026, 22:57 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2. veebr 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2. veebr 2026, 21:51 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. veebr 2026, 21:49 UTC

Tulu

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2. veebr 2026, 21:39 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:36 UTC

Tulu

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2. veebr 2026, 21:34 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:28 UTC

Omandamised, ülevõtmised, äriostud

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2. veebr 2026, 21:23 UTC

Tulu

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2. veebr 2026, 21:19 UTC

Tulu

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2. veebr 2026, 21:17 UTC

Tulu

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2. veebr 2026, 21:17 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:10 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:08 UTC

Tulu

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2. veebr 2026, 21:07 UTC

Tulu

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q Net $608.7M >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q Rev $1.41B >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q Adj EPS 25c >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q EPS 24c >PLTR

2. veebr 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Embecta Corp Prognoos

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

0

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

107 / 352 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Embecta Corp

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
help-icon Live chat